Cancer survivors have a high prevalence of chronic pain.
CDC guidelines published in 2016 on prescribing opioids for chronic pain prompted questions regarding their application to patients with cancer and sickle cell anemia.
Cancer patients more likely to use sublingual tincture form; noncancer patients often use vaporization form
Lazanda (transmucosal immediate release fentanyl [TIRF]) is now available at a 300 mcg dose strength to treat breakthrough cancer pain.
Rotation to methadone as a second-line opioid may be safe and efficacious when using a tiered scheme with close follow-up in patients.
Low-dose morphine may effectively reduce pain intensity compared with weak opioids in patients with cancer who have moderate pain.
A single infusion of ibandronate had outcomes similar to a single dose of radiotherapy for metastatic bone pain in prostate cancer.
Reciprocal relationship between cancer and neurons at play in cancer tumor proliferation and pain sensitization.
For early-stage breast cancer treated with aromatase inhibitors (AIs), arthralgia is improved with omega-3 fatty acid (O3-FA) and placebo.
Almost half of colorectal cancer (CRC) survivors with pain interference (PI) during the initial phase of care have continued PI post-treatment.